Insulin-like growth factor-1 receptor-targeted therapy for non-small cell lung cancer: a mini review

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Lung cancer remains a leading cause of cancer incidence and mortality worldwide.
• Protein tyrosine kinases are emerging as critical targets for lung cancer therapy.
• Insulin-like growth factor-1 receptor (IGF-1R) is implicated in cell growth, survival, and angiogenesis, processes vital to cancer progression.

Purpose of the Study:

• To review the role of IGF-1R in lung cancer development and progression.
• To explore the mechanisms of aberrant IGF-1R activation in lung cancer.
• To discuss current and preclinical IGF-1R antagonists for lung cancer treatment.

Main Methods:

• Literature review of recent research on IGF-1R in lung cancer.
• Analysis of IGF-1R structure, function, and aberrant activation pathways.
• Evaluation of IGF-1R-targeted therapies, including antibodies and small molecule inhibitors.

Main Results:

• Aberrant IGF-1R activation is common in lung cancer, correlating with malignant transformation and poor prognosis.
• IGF-1R signaling contributes to key oncogenic effects, including proliferation, survival, and angiogenesis.
• Various IGF-1R antagonists, including antibodies and small molecule tyrosine kinase inhibitors, show therapeutic potential.

Conclusions:

• IGF-1R is a significant molecular target in lung cancer.
• Targeting IGF-1R offers a promising therapeutic strategy for lung cancer patients.
• Further clinical investigation of IGF-1R antagonists is warranted.